|
LCMT2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.40479999966026E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.98950000052901E-07 |
| Normal-vs-Stage2 |
8.574500E-04 |
| Normal-vs-Stage3 |
3.3033000002014E-08 |
| Normal-vs-Stage4 |
2.85900003671458E-09 |
| Stage1-vs-Stage2 |
5.530800E-01 |
| Stage1-vs-Stage3 |
6.773800E-02 |
| Stage1-vs-Stage4 |
6.981300E-03 |
| Stage2-vs-Stage3 |
9.864200E-02 |
| Stage2-vs-Stage4 |
2.099900E-02 |
| Stage3-vs-Stage4 |
2.309200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.64570000019226E-07 |
| Normal-vs-AfricanAmerican |
2.435400E-03 |
| Normal-vs-Asian |
5.99900000000098E-05 |
| Caucasian-vs-AfricanAmerican |
6.749800E-01 |
| Caucasian-vs-Asian |
7.375800E-01 |
| AfricanAmerican-vs-Asian |
8.844000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.38990000012151E-08 |
| Normal-vs-Female |
1.16700005214909E-09 |
| Male-vs-Female |
8.705600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.21939999997834E-07 |
| Normal-vs-Age(41-60Yrs) |
1.05320000498565E-08 |
| Normal-vs-Age(61-80Yrs) |
4.33510000119597E-08 |
| Normal-vs-Age(81-100Yrs) |
5.976300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.232800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.327800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.340200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.971400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.819000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.101400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.001100E-03 |
| Classical-VS-Follicular |
7.969700E-02 |
| Classical-VS-Other |
8.031700E-02 |
| Classical-VS-Normal |
4.60489999998259E-06 |
| Tall-VS-Follicular |
2.099800E-01 |
| Tall-VS-Other |
5.113400E-01 |
| Tall-VS-Normal |
1.39419999989343E-08 |
| Follicular-VS-Other |
3.130400E-01 |
| Follicular-VS-Normal |
1.42019999982423E-07 |
| Other-VS-Normal |
1.818630E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.15589999688726E-08 |
| Normal-vs-N1 |
5.54839999500345E-08 |
| N0-vs-N1 |
1.621950E-01 |
|
|
